Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07612774 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS

Study acronym: CAPRA-EVO
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion moved earlier from Dec 31, 2028 to Oct 31, 2028 Show 5 more changesShow less
    • Study completion pushed from Jan 31, 2029 to Dec 31, 2029
    • Enrollment target: 233 to 232
    • Study sites: 1 to 2
    • Start date changed from estimate of May 19, 2026 to Nov 19, 2025
    • Eligibility criteria expanded, about 16 words
  2. Eligibility criteria expanded, about 16 words
    • Study title revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The CAPRA-EVO trial is a single-center, randomized, open-label study with blinded endpoint assessment comparing early evolocumab plus standard lipid-lowering therapy versus standard-of-care lipid-lowering therapy in patients with acute coronary syndrome after successful percutaneous coronary intervention. The study will use serial photon-counting coronary computed tomography angiography at baseline and 52 weeks to assess changes in non-culprit coronary plaque burden and stenosis severity. Secondary outcomes include changes in high-risk plaque features, lipid and inflammatory biomarkers, cardiovascular events, and safety outcomes. The trial aims to determine whether early intensive LDL-C lowering with evolocumab can reduce coronary plaque progression and support PCCT-CCTA as a noninvasive tool for monitoring atherosclerotic plaque dynamics.
Trial Details
NCT Number NCT07612774
Lead Sponsor West China Hospital
Conditions
(from sponsor)		 Coronary, Coronary Artery Disease
Related terms Acute Coronary Syndrome, Coronary Artery Disease, Hypercholesterolemia, Autosomal Dominant, 3
Enrollment 232 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov